Form 4: Castle Biosciences Director Acquires RSUs
Statement of Changes in Beneficial Ownership
Castle Biosciences Director Tiffany Olson acquired 13,667 Restricted Stock Units (RSUs) on May 22, 2026, as detailed in a Form 4 filing.
Summary
- Tiffany Olson, a Director at Castle Biosciences, Inc., acquired 13,667 Restricted Stock Units (RSUs) on May 22, 2026.
- These RSUs represent the right to receive one share of the Issuer's Common Stock per unit.
- The RSUs are set to vest in full on the earlier of the one-year anniversary of the grant date (May 22, 2026) or the day before the next Annual Meeting of Stockholders.
- Following this acquisition, Ms. Olson beneficially owns 39,573 shares of Common Stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard equity award to a director rather than a significant new investment or divestment.
Positives
- Director acquisition of equity signals confidence in the company's future prospects.
- The acquisition of RSUs is a standard form of executive compensation, aligning management interests with shareholders.
Future Outlook
The RSUs vest on the earlier of May 22, 2027, or the day before the next Annual Meeting of Stockholders, indicating a future potential increase in Ms. Olson's direct shareholding.
Industry Context
StockSavvy.ai notes that director equity awards are common in the biotechnology and healthcare sectors, reflecting long-term incentive structures and alignment with company performance.
Stakeholder Impact
- Shareholders: The acquisition of RSUs by a director can be seen as a positive signal of commitment and alignment with shareholder interests.
- Employees: Standard practice for executive compensation, reinforcing the company's incentive structure.
Next Steps
- Vesting of Restricted Stock Units on May 22, 2027, or prior to the next Annual Meeting of Stockholders.
- Potential conversion of RSUs to common stock upon vesting.
Key Dates
| Date | Description |
|---|---|
| 05/22/2026 | Date of earliest transaction and RSU acquisition. |
| 05/27/2025 | Date of signature on the filing. |
Keywords
Castle Biosciences, CSTL, Form 4, Restricted Stock Units, RSUs, Director, Beneficial Ownership, Equity Award
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.